首页> 外国专利> Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs

Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs

机译：使用抗康蛋白剂来调节精神药物的治疗效果

页面导航

摘要
著录项
相似文献

摘要

The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

机译：本发明首先涉及含有至少一种Cankexin阻断剂和精神药物作为组合产品的产物，作为患有精神病和/或神经变性疾病的患者同时使用或随时间使用的组合产品。 Connexin-封闭剂有利地选自甲氯芬酸，18-β-甘油吡咯烷酸，碳氧酮，Mefrooquine和2-APB的基团，优选由梅氟磺酸组成。本发明首先涉及含有至少一种Cankexin阻断剂和精神药物作为组合产品的产物，作为患有精神病和/或神经变性疾病的患者同时使用或随时间使用的组合产品。 Connexin-封闭剂有利地选自甲氯芬酸，18-β-甘油吡咯烷酸，碳氧酮，Mefrooquine和2-APB的基团，优选由梅氟磺酸组成。

著录项

公开/公告号US11077080B2

专利类型
公开/公告日2021-08-03

原文格式PDF
申请/专利权人 COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES;BIO MODELING SYSTEMS OU BMSYSTEMS;
展开▼

申请/专利号US201514736004
发明设计人 FRANCK MOUTHON;MATHIEU CHARVERIAT;JEAN-PHILIPPE DESLYS;FRANÇOIS IRIS;
展开▼

申请日2015-06-10
分类号A01N43;A01N43/46;A61K31/55;A61K31/196;A61K31/4525;A61K31/5513;A61K31/551;A61K31/165;A61K31/135;A61K31/137;A61K31/343;A61K31/56;A61K45/06;
国家 US
入库时间 2022-08-24 20:18:52

相似文献

专利
外文文献
中文文献